LEXINGTON, KY. — This is an official press release from the U.S. Department of Justice (USAO - Kentucky, Eastern), published as received.
LEXINGTON, Ky. – A Booneville, Kentucky pharmacy, Public Drug Company, d/b/a Booneville Discount Drugs, has agreed to pay the United States $250,000 to settle civil allegations that it failed to make and maintain complete and accurate records of its controlled substances, in violation of the federal Controlled Substances Act (“CSA”).
Under the CSA, pharmacies authorized to possess controlled substances are required to maintain complete and accurate records of each controlled substance received, dispensed, and disposed. The U.S. Drug Enforcement Administration (“DEA”) has the authority to inspect the records of these pharmacies and verify that their controlled substances records are complete and accurate in compliance with the CSA.
The United States alleged that Booneville Discount Drugs failed to maintain complete and accurate records of its controlled substances inventories from November 25, 2016 to April 25, 2018. In an audit performed by the DEA, Booneville Discount Drugs’ records did not account for observed shortages of oxycodone and methadone in its inventories during this time period. Booneville Discount Drugs also self-disclosed its recordkeeping discrepancies of controlled substances to the DEA.
The Government’s work in this investigation illustrates its commitment to combatting violations of controlled substances laws. Tips from all sources about possible violations of controlled substances laws can be reported to the DEA at www.dea.gov/submit-tip.
The DEA, Diversion Control Division conducted the investigation of alleged violations. Assistant United States Attorney Meghan Stubblebine represented the United States. The claims resolved by the settlement are allegations only, and there has been no determination of liability.
– END –
